This method results in the inclusion of Medicaid prescriptions and gross spending for: Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity, Wegovy, Zepbound, Saxenda, and generic liraglutide as well as a small number of prescriptions and spending for Adlyxin, Byetta, Bydureon BCise, and Tanzeum (now discontinued)
To maintain the results of a weight loss medication, you should expect to continue taking it long-term
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database